beeldscherm schreef op 9 augustus 2018 11:22:
[...]
Unknowns Relating to Treatment Benefits
The safety population examined during the pre- and post- approval studies of CINRYZE consisted
primarily of Caucasian (white) patients. Non-Caucasian patients were not very well represented
in the safety population. It is not believed that different ethnic groups would react differently to
CINRYZE because C1 INH is a human plasma protein not which is not subject to metabolism by
the liver, excretion or drug interactions, however this remains missing information
zet eea ook in een ander daglicht.
misschien heeft Loukisha daarom zulke heftige reactie en pijn gehad van Cinryze zij is immers donker dus Non-Caucasian